Psychedelics-Assisted Therapy

Multi-awarded singer Dua Lipa has been interviewing some interesting folks in her BBC’s “At Your Service” series. This season she invited psychedelics pioneering researcher and advocate Amanda Feilding, aka “the Queen of Psychedelics” or also “The High Priestess...

The Alexander Shulgin Research Institute (ASRI), the organization advancing the renowned chemist’s scientific work and legacy, presented novel psychoactive compounds at the MAPS' Psychedelic Science 2023 last month in Denver.   ASRI co-founder and president Dr....

Clinical-stage biopharma psychedelics company Seelos Therapeutics Inc. (NASDAQ: SEEL) announced it has dosed the first patients in a Phase 1 study with healthy adult Japanese and non-Asian participants to compare the safety and pharmacokinetic (PK) profiles of proprietary intranasal racemic...

Alto Neuroscience Inc. received an additional $25 million in equity investment by Alpha Wave Ventures, bringing total Series B raised funding to approximately $60 million and total equity capital raised to approximately $100 million since its foundation in 2019, plus a recently...

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. The projects are part of a collaboration with technology transfer company Yissum, a business partner of renowned firms...

Missouri Rep. Tony Lovasco (R) recently came through on his announced plan of filing a psychedelics bill with a revised measure that calls for legal psilocybin therapy for serious mental health cases, as first noted by Marijuana Moment. The new house bill HB 869 would allow for psilocybin use...

Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004. Anxiety disorders are the most common mental health...

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction. The company closed a private placement deal — with the original offer extended to Quebec-based investors — issuing more than 28.6...

Two psychedelics companies have shared their updates and key milestones to be reached this 2023. The 5-MeO-DMT Business Clinical-stage biopharma company GH Research PLC (NASDAQ: GHRS) has received initial regulatory and ethical approvals to commence a multi-site Phase 2b trial for its lead product...

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its novel DMT-based synthetic compound. Conducted at Hammersmith Medicines Research Ltd. in the U.K.,...

Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's Senate Health Committee. By prefiling the bill, Democratic sponsors Reps. Linda Rosenthal, Jo...

Psychedelics have made it to Capitol Hill. On Thursday Congress announced the creation of a Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus. Led by Representatives Lou Correa (D-CA) and Jack Bergman (R-MI), the caucus will consist of bipartisan members of Congress...

Psychedelics-assisted therapy provider Field Trip Health & Wellness Ltd. has launched Freedom by Field Trip, a novel and unmatched one-year hybrid program combining ketamine-assisted therapy (KAP) with holistic wellness support. Initially available in California and Washington state, non-...

Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begun dosing in its IND-enabling study of proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia.  This safety evaluation trial will be conducted by Experimur, a...

Clinical-stage psychedelics company atai Life Sciences N.V. (NASDAQ: ATAI) reported its financial results for the quarter ended September 30, 2022 and shared business developments. Numbers show the company ended Q3 2022 with a cash position of $304.1 million, which combined with committed...